^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)

    i
    Other names: SIGLEC5, Sialic Acid Binding Ig Like Lectin 5, OB-BP2, SIGLEC-5, CD33L2, CD170, Sialic Acid-Binding Ig-Like Lectin 5, Obesity-Binding Protein 2, OB-Binding Protein 2, CD33 Antigen-Like 2, OBBP2, Sialic Acid-Binding Immunoglobulin-Like Lectin 5, Sialic Acid Binding Ig-Like Lectin 5, CD170 Antigen, Siglec-5
    Associations

    News

    Trials
    2ms
    Development of a Multilayered Prognostic Model for Wilms' Tumor Based on Characteristic Lymphocyte Genes. (PubMed, Genet Res (Camb))
    Elevated immune cell infiltration and enhanced drug sensitivity characterized the high-risk group, exhibiting significant responsiveness to chemotherapy, targeted, and immunotherapy treatments (p < 0.05). The study developed an integrated LGCPN-WT model, significantly enhancing survival prediction accuracy and clinical utility for WT, thus supporting personalized treatment approaches.
    Journal • IO biomarker
    |
    MLLT3 (MLLT3 Super Elongation Complex Subunit) • KLRC1 (Killer Cell Lectin Like Receptor C1) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)
    2ms
    Siglec-14-LGALS3BP glycoimmune axis shapes tumor-associated macrophage polarization and confers poor outcome in colorectal cancer. (PubMed, NPJ Precis Oncol)
    Siglec-14-positive CRC patients exhibited elevated serum LGALS3BP, which correlated with advanced progression and poorer survival. Collectively, these findings establish the LGALS3BP-Siglec-14 axis as a potential therapeutic target, offering a strategy to enhance antitumor immunity in Siglec-14-positive CRC patients.
    Journal
    |
    SPP1 (Secreted Phosphoprotein 1) • LGALS3 (Galectin 3) • LGALS3BP (Lectin galactoside-binding soluble 3-binding protein) • SIGLEC14 (Sialic Acid Binding Ig Like Lectin 14) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)
    3ms
    Integration of Mendelian randomization and transcriptome wide association studies for causal gene identification in ovarian cancer genetic architecture. (PubMed, Discov Oncol)
    This study provides robust genetic evidence for causal relationships between specific gene expression patterns and ovarian cancer risk.
    Journal
    |
    CD22 (CD22 Molecule) • SIGLEC14 (Sialic Acid Binding Ig Like Lectin 14) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)
    6ms
    Hypoxia suppressed the Siglec-5 signaling in TAMs via modulating the balance of SHP2/SYK activation in hepatocellular carcinoma. (PubMed, Sci Rep)
    Hypoxia suppressed the Siglec-5 signaling in TAMs via modulating the balance of SHP2/SYK activation in hepatocellular carcinoma.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • SYK (Spleen tyrosine kinase) • ARG1 (Arginase 1) • IL1B (Interleukin 1, beta) • NOX4 (NADPH Oxidase 4) • SIGLEC14 (Sialic Acid Binding Ig Like Lectin 14) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)
    8ms
    CD16 and Siglec expression refine the phenotypic heterogeneity of steady-state myeloid-derived suppressor cells. (PubMed, Front Oncol)
    These results demonstrate that Siglecs are differentially expressed on neutrophil subsets, and along with CD16, may be used to help further define what is a PMN-MDSC. Consistent with current observations by others, PMN-MDSCs may encompass an array of neutrophil subtypes, including low-density neutrophils, and point to the need for more work to precisely define the genetic signatures of PMN-MDSCs.
    Journal
    |
    CD33 (CD33 Molecule) • CEACAM8 (CEA Cell Adhesion Molecule 8) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)
    9ms
    Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study. (PubMed, Signal Transduct Target Ther)
    Furthermore, a multimodal model was constructed and validated for stratifying ES-SCLC into high or low risk to predict the immunotherapy efficacy. This study sheds light on harnessing local and systematic immune profiles to better stratify patients with ES-SCLC for immunotherapy and putative combinational treatment.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD163 (CD163 Molecule) • CD70 (CD70 Molecule) • CD68 (CD68 Molecule) • CSF1R (Colony stimulating factor 1 receptor) • ITGAE (Integrin Subunit Alpha E) • CCL3 (C-C Motif Chemokine Ligand 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)
    |
    Tyvyt (sintilimab)
    12ms
    Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel). (PubMed, Front Oncol)
    The 6-GES was reduced, whereas the 17-GES was elevated at progression post axi-cel, consistent with the notion that these signatures represent features relevant for response and resistance to CAR T-cell therapy. Our transcriptomic analysis identified gene expression signatures potentially predictive of outcome with CD19-directed CAR T-cell therapy, and these findings are informative for risk stratification and development of next-generation products.
    Journal • IO biomarker
    |
    ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • ARID1A (AT-rich interaction domain 1A) • CD19 (CD19 Molecule) • KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • CCL2 (Chemokine (C-C motif) ligand 2) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • SLC16A1 (Solute Carrier Family 16 Member 1) • CCL22 (C-C Motif Chemokine Ligand 22) • SOX11 (SRY-Box Transcription Factor 11) • TNFSF4 (TNF Superfamily Member 4) • DUSP5 (Dual Specificity Phosphatase 5) • KLRB1 (Killer Cell Lectin Like Receptor B1) • NKG2D (killer cell lectin like receptor K1) • SERPINA9 (Serpin Family A Member 9) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)
    |
    Yescarta (axicabtagene ciloleucel)
    12ms
    A blood-based liquid biopsy analyzing soluble immune checkpoints and cytokines identifies distinct neuroendocrine tumors. (PubMed, J Exp Clin Cancer Res)
    The analysis of soluble immunological factors in blood presents a promising liquid biopsy approach for identifying NENs, delivering critical insights for both prognosis and diagnosis. This study serves as a proof-of-concept for an innovative clinical tool that holds the potential to transform the management of these rare malignancies, providing a non-invasive and effective method for early detection and disease monitoring.
    Journal • Liquid biopsy
    |
    IL6 (Interleukin 6) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD27 (CD27 Molecule) • IL4 (Interleukin 4) • ISG20 (Interferon Stimulated Exonuclease Gene 20) • LGALS9 (Galectin 9) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)
    1year
    Integrative Multi-omics Analysis and Mendelian Randomization Reveal Potential Therapeutic Targets and their Stratification in Lung Squamous Cell Carcinoma. (PubMed, Curr Med Chem)
    In this study, we identified 3 tier-one genes (MCM6, C4B, CTC-463A16.1), 7 tier-two genes (C4A, HLA-DRB9, LIMS2, LINC00654, MYO7B, SIGLEC5, TIE1), and 13 tier-three genes (AC007743.1, AC147651.4, ALDH2, BTN3A2, BTNL9, CCR1, GIPC3, HLA-DQB1, ICAM5, LIMD1, PM20D1, RP11-302L19.3, RP11-768F21.1).
    Journal • IO biomarker
    |
    HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • ALDH2 (Aldehyde Dehydrogenase 2 Family Member) • BTN3A2 (Butyrophilin Subfamily 3 Member A2) • ICAM5 (Intercellular Adhesion Molecule 5) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5) • MCM6 (Minichromosome Maintenance Complex Component 6)
    over1year
    The immunomodulatory ballet of tumour-derived extracellular vesicles and neutrophils orchestrating the dynamic CD73/PD-L1 pathway in cancer. (PubMed, J Extracell Vesicles)
    Targeting P1R on NØ, particularly A3R, exhibited potential therapeutic strategy to counteract immunosuppression in HNSCC. Understanding the TEX-mediated crosstalk between tumours and NØ offers insights into immunomodulation for improving cancer therapies.
    Journal • PD(L)-1 Biomarker • IO biomarker • Immunomodulating
    |
    CDK4 (Cyclin-dependent kinase 4) • CD73 (5'-Nucleotidase Ecto) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)
    2years
    Identification of therapeutic targets and prognostic biomarkers in the Siglec family of genes in tumor immune microenvironment of sarcoma. (PubMed, Sci Rep)
    Furthermore, a significant correlation was found between the somatic copy number changes of all Siglec molecules and the abundance of immune infiltrates. Our study paints a promising vision for the development of immunotherapy drugs and the construction of prognostic stratification models by investigating the therapeutic and prognostic potential of the Siglec family for SARC.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • MUC16 (Mucin 16, Cell Surface Associated) • CD22 (CD22 Molecule) • CD4 (CD4 Molecule) • STING (stimulator of interferon response cGAMP interactor 1) • SIGLEC15 (Sialic Acid Binding Ig Like Lectin 15) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)
    |
    TP53 mutation
    2years
    SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity. (PubMed, Int J Mol Sci)
    Moreover, the interaction between sialic acids and SIGLEC-5/14-consequently hindered trogocytosis and tumor cell killing. In summary, our results provide evidence that the sialic acid-SIGLEC-5/14 interaction is an additional target for innate checkpoint blockade in the tumor microenvironment.
    Journal • Tumor cell
    |
    ITGAM (Integrin, alpha M) • ITGB2 (Integrin Subunit Beta 2) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5) • SIRPA (Signal Regulatory Protein Alpha)